Engineered immune cells take on Hard-to-Treat lymphoma in new trial
NCT ID NCT07271121
First seen Jan 05, 2026 · Last updated May 22, 2026 · Updated 25 times
Summary
This study tests a one-time treatment using the patient's own immune cells, modified to attack cancer cells, in adults with a type of blood cancer (non-Hodgkin lymphoma) that has come back or not responded to standard therapy. The goal is to see how well the treatment shrinks tumors and to monitor side effects. About 26 participants will receive a single dose and be followed for one year.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NON-HODGKIN LYMPHOMA REFRACTORY/ RELAPSED are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
King Hussein Cancer Center
RECRUITINGAmman, 11941, Jordan
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.